Role of chemotherapy and biomolecular therapy in the treatment of uterine sarcomas. Review uri icon

Overview

abstract

  • Uterine sarcomas are rare, high-risk malignancies. Expert histologic review is important for accurate diagnosis. For high-grade leiomyosarcomas, the risk of recurrence is high after complete resection of uterus-limited disease; however, no adjuvant therapy has been proven to improve survival. Chemotherapy regimens with efficacy in treating advanced uterine leiomyosarcoma include gemcitabine-docetaxel, doxorubicin and ifosfamide. Uterine carcinosarcomas also carry a high risk of recurrence. Adjuvant chemotherapy is a standard approach for completely resected and metastatic carcinosarcoma. Active agents include carboplatin, cisplatin, ifosfamide and paclitaxel.

publication date

  • July 14, 2011

Research

keywords

  • Antineoplastic Agents
  • Sarcoma
  • Uterine Neoplasms

Identity

Scopus Document Identifier

  • 80055056022

Digital Object Identifier (DOI)

  • 10.1016/j.bpobgyn.2011.06.003

PubMed ID

  • 21752717

Additional Document Info

volume

  • 25

issue

  • 6